title: Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center.
abstract: BACKGROUND
  Pancreatic metastasis accounts for 2% to 11% of all mRCC cases. The prognostic value of pancreatic metastases in the era of TTs is unclear. We evaluated outcomes in a cohort of mRCC patients with pancreatic metastases (PmRCC) who were treated with TTs.
  
  
  METHODS
  We retrospectively reviewed the records of 354 mRCC patients treated at our institute between January 2005 and June 2012. Differences in terms of OS between this unselected cohort of mRCC patients and a subgroup of patients with PmRCC were investigated. Kaplan-Meier and log-rank test methods were used to evaluate OS.
  
  
  RESULTS
  In total, 24 PmRCC (7%) patients were identified, and were compared with a cohort of 330 mRCC patients with metastasis at other sites. Pancreatic metastases were synchronous in 3 patients, and they were metachronous in 11 patients. Surgical resection of pancreatic metastases was performed in 2 (8%) patients. At a maximum follow-up of 89 months (median, 51 months), median OS was 39 months in PmRCC patients, vs. 23 months in the mRCC patient group (P = .0004).
  
  
  CONCLUSIONS
  Among mRCC patients treated with TTs, the presence of pancreatic metastasis seems to be associated with a longer survival than the presence of metastasis at other sites.
authors.affiliation: Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Grassi
authors.forename: Elena
authors.initials: E
authors.lastname: Verzoni
authors.forename: Luigi
authors.initials: L
authors.lastname: Mariani
authors.forename: Filippo
authors.initials: F
authors.lastname: De Braud
authors.forename: Jorgelina
authors.initials: J
authors.lastname: Coppa
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Mazzaferro
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Procopio
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007558:Italy; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D013534:Survival
keywords: Pancreas; Renal cell carcinoma; Targeted therapy; Tyrosine kinase inhibitors; mTOR inhibitors